Fundraising Fox
/Companies
Sign in

Pykus Therapeutics

Cambridge, US · Founded 2016 · Delaware corporation · 12 employees on LinkedIn · 2 known investors

Find your way into Pykus Therapeutics

Sign up to see every warm intro you have to Pykus Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Pykus Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Pykus Therapeutics is a clinical-stage medical technology company developing biodegradable polymers for vitreoretinal surgery. Its lead product, PYK-2101, is a biodegradable hydrogel intended to help patients recover from retina surgery faster and more comfortably.

BiotechHealthtechMedical Devices

Founders & leadership

Pykus Therapeutics was founded in 2016 by James (Tony) Stefater, Tony Stefater, MD, PhD, and Tommy Stryjewski, MD.

J(James (Tony) Stefater
James (Tony) StefaterCofounder & President
TSTony Stefater, MD, PhD
Tony Stefater, MD, PhDPresident & Cofounder
TSTommy Stryjewski, MD
Tommy Stryjewski, MDChief Scientific Officer, Cofounder, Director
MSMichael Singer
Michael SingerNamed on SEC filing
RL
Richel LiuNamed on SEC filing
TP
Thomas P. StryjewskiNamed on SEC filing
SS
Sameer SabirNamed on SEC filing
CBCarl Berke
Carl BerkeBoard MemberGeneral Partner at Mass General Brigham Ventures

Investors · 2

ShangBay Capital LLClisted by ShangBay Capital LLCPalo Alto

How we know: ShangBay Capital LLC's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$2.5M disclosed across 1 round · 2020

▶$2.5MraisedFeb 2021 · 32 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • James A. StefaterExecutive Officer
  • Michael SingerDirector
  • Richel LiuDirector
  • Thomas P. StryjewskiDirector
  • Sameer SabirDirector
  • Carl BerkeDirector
Offering amount
$2.5M
Amount sold
$2.5M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

AvttxAVTTX is a clinical-stage company developing gene therapy treatments for retinal and ophthalmologic diseases. The company leverages adeno-associated virus (AAV) technology to address unmet medical needs in vision care.
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.

Companies working in the same space as Pykus Therapeutics.

Frequently asked questions

What does Pykus Therapeutics do?
Pykus Therapeutics is a clinical-stage medical technology company developing biodegradable polymers for vitreoretinal surgery. Its lead product, PYK-2101, is a biodegradable hydrogel intended to help patients recover from retina surgery faster and more comfortably.
Who founded Pykus Therapeutics?
Pykus Therapeutics was founded by James (Tony) Stefater, Tony Stefater, MD, PhD, Tommy Stryjewski, MD in 2016.
Who are Pykus Therapeutics's investors?
Pykus Therapeutics's investors include Beacon Angels, ShangBay Capital LLC.
How much funding has Pykus Therapeutics raised?
Pykus Therapeutics has disclosed $2.5M raised across 1 round.
Where is Pykus Therapeutics headquartered?
Pykus Therapeutics is headquartered in Cambridge, US.